10x Genomics (TXG) CFO sells 11,888 shares at about $19

10x Genomics, Inc. (TXG) reported an insider stock transaction by its Chief Financial Officer.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) reported an insider stock transaction by its Chief Financial Officer. On 11/24/2025, the CFO disposed of 11,888 shares of Class A common stock in a sale transaction at a price of $18.9983 per share. After this transaction, the officer beneficially owns 297,385 shares of Class A common stock in direct ownership form.

The company notes that the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, meaning the transaction was connected to equity compensation rather than an open-market liquidation of a larger personal position.

Insider Trade Summary

Net Seller: 11,888 shares

Net Sell 1 txn

Insider Taich Adam

Role Chief Financial Officer

Sold 11,888 shs ($226K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	11,888	$18.9983	$226K

Holdings After Transaction: Class A Common Stock — 297,385 shares (Direct)

Footnotes (1)

1. F1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

FAQ

What insider transaction did 10x Genomics (TXG) report in this Form 4?

The Chief Financial Officer of 10x Genomics (TXG) reported a sale of 11,888 shares of Class A common stock on 11/24/2025.

At what price were the TXG shares sold by the CFO?

The 11,888 shares of Class A common stock were sold at a price of $18.9983 per share.

How many 10x Genomics (TXG) shares does the CFO own after the transaction?

Following the reported transaction, the Chief Financial Officer beneficially owns 297,385 shares of TXG Class A common stock in direct ownership.

Why did the 10x Genomics (TXG) CFO sell shares in this filing?

The filing states that the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.

What type of security was involved in the TXG insider transaction?

The transaction involved Class A common stock of 10x Genomics, Inc.

Does this TXG Form 4 report any derivative securities activity?

The filing includes a table for derivative securities, but no specific options, warrants, or other derivatives are listed as acquired or disposed of.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taich Adam

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/24/2025		S(1)		11,888	D	$18.9983	297,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Eric S. Whitaker, as Attorney-in-Fact for Adam Taich	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.